Monoclonal antibodies in gynecological cancer: a critical point of view. - Wikidata - wikimedia - TriplyDB

Monoclonal antibodies in gynecological cancer: a critical point of view.

Monoclonal antibodies in gynecological cancer: a critical point of view.

http://www.wikidata.org/entity/Q35659915

about

Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.Malignant ascites: pathophysiology and treatment.Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine Role of the EpCAM (CD326) in prostate cancer metastasis and progression.Monoclonal antibodies therapies for ovarian cancer.Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.Cediranib in ovarian cancer: state of the art and future perspectives.Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?Doppler Ultrasound Flow Evaluation of the Uterine Arteries Significantly Correlates with Tumor Size in Cervical Cancer Patients.

P2860

Q26828581-7CA2C13E-D820-4509-8DFB-8BED77B85198 Q33911286-ED558C8A-0A3E-42C6-8481-5065B9FD341A Q34213359-24BF57AE-09B9-4E5E-8C43-70B6B8B03A19 Q34922631-26F83E87-BCE1-45A6-AD60-F970DB1FCF29 Q37224420-E0F76694-BDE3-4277-8943-07DFAF319B4E Q38020426-9EFB0077-4F24-4C2A-8384-3036EB899A9A Q38078400-7CDE3579-3451-49FF-AAE6-8FF2C7926840 Q38616195-AC932799-4C8A-4AA5-BE93-8A24B1D1B94A Q38692683-77EBF556-6971-4D11-905B-86B2EAA99A37 Q39274912-CBBA099C-6D08-4589-93AB-F1CA55474113 Q43300329-AE8BA208-0443-4279-9363-B26069A70AC5 Q47383627-AD1F7CCC-4EC8-4092-93C1-477BEFF9571F

P2860

Monoclonal antibodies in gynecological cancer: a critical point of view.

http://www.wikidata.org/entity/Q35659915

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Monoclonal antibodies in gynecological cancer: a critical point of view.

@ast

Monoclonal antibodies in gynecological cancer: a critical point of view.

@en

type

label

Monoclonal antibodies in gynecological cancer: a critical point of view.

@ast

Monoclonal antibodies in gynecological cancer: a critical point of view.

@en

prefLabel

Monoclonal antibodies in gynecological cancer: a critical point of view.

@ast

Monoclonal antibodies in gynecological cancer: a critical point of view.

@en

P1433

Q35659915-0E015B9E-7423-4B7A-8D54-C56CAFAEF6AE

P1476

Q35659915-63F29AAE-1B76-43A1-A3E5-A1BF242743B2

P2093

Q35659915-60AB4B61-92B3-4F73-9850-65269888B0F5

Q35659915-70392B85-9B92-4E20-9E27-1E090D23CF20

Q35659915-A5DDF777-815D-49BF-A141-EA49334DED6C

Q35659915-A8FCAB7B-C3F1-45A0-B421-F2DBF2E3C080

Q35659915-B1C004AD-6CBC-4DAB-AF9C-6E15139F0B95

Q35659915-CBA5AFDE-CC14-42B4-9F7F-FECDE2B99037

P275

Q35659915-F61DC95A-69D5-4875-9323-112C44343D6C

P2860

Q35659915-03AB2446-69E8-485B-8B3F-2C3CCC84799F

Q35659915-03F6920C-A1CF-42B3-AB2E-0522020B9675

Q35659915-070CB0FD-0D88-4FBB-85C7-A0F0065AA16B

Q35659915-087C031A-888F-4586-8FE1-BE214B4C63D0

Q35659915-09BBF051-215E-46DD-BEBB-2BF3B22BEE40

Q35659915-0A0A7FEF-5A4E-4C59-AA98-6245B859EB3E

Q35659915-0A968EE6-22D5-4549-A4AC-74A6484F7A59

Q35659915-127FB76B-0570-4A44-A09A-268A488B5EE3

Q35659915-140D86B6-AEAC-4332-A5AF-A0BE86228B65

Q35659915-14C1A34A-A09D-483B-A61A-2F5802FD4787

P304

Q35659915-E92EC4E1-754F-4C83-AEE8-F43E9DB757A8

P31

Q35659915-4ABF7131-0F3C-4B6D-8B30-49F0CFA8B653

Q35659915-ACA5DB26-2DE9-4864-B614-5AB4CEDD9F53

P356

Q35659915-61D75E42-68EA-435F-A7D2-D2053A2D8308

P478

Q35659915-0641B263-CF38-4779-8DA5-10D4E1BCB137

P50

Q35659915-3833A964-3BF1-43AB-B83D-6E673028EDCD

Q35659915-7F9631EF-AEB5-4E44-8AB8-117FC7387119

Q35659915-889FE228-0012-45CD-8BEF-34A680738BDD

Q35659915-90E73E60-39A4-4CC5-913A-6829B7C12BB2

P5008

Q35659915-7FFCB420-3F0D-4E1B-A7F6-C94792555CCF

P577

Q35659915-7380AD7D-883E-4C96-AA1A-C99E3B1AC8E4

P5875

Q35659915-B113C4BA-0A44-4B92-A8AC-950D38FF9C3C

P698

Q35659915-F4589DF9-A274-458D-8FD9-2FEE0818A909

P921

Q35659915-34595E13-9C57-4EED-9B05-676DB680FBD9

Q35659915-75380F86-ED83-4FB7-8B8F-258BAE193567

Q35659915-90CBA775-1788-442B-A0A0-A75DBF121016

Q35659915-A6CAFA28-7DE3-40E8-A60D-450561E7699A

Q35659915-AF37E3BA-046C-42BE-A89D-ED61FCA44090

Q35659915-C84C7C39-5B5E-466E-B1DD-9ABCD0C635D2

P932

Q35659915-CEFDDB68-93C7-40CD-B91E-09085839D916

P356

P1433

Clinical and Developmental Immunology

P1476

Monoclonal antibodies in gynecological cancer: a critical point of view.

@en

P2093

Aurelia Rughetti

http://www.w3.org/2001/XMLSchema#string

Ilaria Grazia Zizzari

http://www.w3.org/2001/XMLSchema#string

Jlenia Caccetta

http://www.w3.org/2001/XMLSchema#string

Marianna Nuti

http://www.w3.org/2001/XMLSchema#string

Pierluigi Benedetti-Panici

http://www.w3.org/2001/XMLSchema#string

Valeria Visconti

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma

Catumaxomab: clinical development and future directions

Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen

Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

P304

890758

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2011/890758

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P50

Filippo Bellati

Maria Luisa Gasparri

P5008

P577

2011-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221738555

http://www.w3.org/2001/XMLSchema#string

P698

22235224

http://www.w3.org/2001/XMLSchema#string

P921

cervical cancer

monoclonal antibody

uterine cervix neoplasm

P932

3253445

http://www.w3.org/2001/XMLSchema#string